Knopman, David S.
Article History
First Online: 8 January 2019
Competing interests
: D.S.K. serves on a Data Safety Monitoring Board (DSMB) for The Dominantly Inherited Alzheimer Network (DIAN) study for which he receives personal compensation. He serves on a DSMB for Biogen, but all compensation related to that activity goes to his institution. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He does not receive any personal compensation from either Biogen or Lilly as a site investigator; his institution receives funding for those activities. He is an adviser to Samus Pharmaceuticals and Alzeca Biosciences. For both, he receives no personal compensation; his institution receives funding for those activities. He receives research support from the NIH. Avid Radiopharmaceuticals, Inc., supplies Mayo Clinic with AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation that is used in research in which D.S.K. is an investigator.